Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole

Helicobacter Pylori Infection Clinical Trial

Official title:

Food Effect on the Eradication Rate of H. Pylori With Triple Therapy With Esomeprazole

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02552641
• Other study ID #: TIMESO
• Status: Withdrawn
• Phase: Phase 4
• Start date: September 2015
• Est. completion date: September 2016

Study information

• Verified date: August 2022
• Source: EMS
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is assess whether the various forms of triple regimen of administration of treatment of Helicobacter pylori (before meals (fasting), after meals, and any independent mealtime) influence the rate of eradication of this bacterium.

Description:

Phase IV, open, randomized, prospective study. - Length of experience: 180 days. - 06 visits. - Evaluation of the efficacy of differences regimens of administration.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 2016
• Est. primary completion date: February 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Participants of both sexes;
• Age greater than or equal to 18 and less than or equal to 50 years;
• Participant diagnosed with type dyspepsia epigastric pain carriers of Helicobacter pylori infection, according to the classification of ROME III;
• Ability to understand and consent to participate in this clinical study, manifested by reading, understanding and signing of the Informed Consent (IC).

Exclusion Criteria:

• Any finding of clinical observation (clinical evaluation / physical) that is interpreted by the investigator as a medical risk to participate in the clinical trial;
• Any laboratory examination found that the investigator doctor considers a risk to the research participant for their participation in the clinical trial;
• Known hypersensitivity to the drug components used during the study;
• Women in pregnancy or breastfeeding period;
• Women in reproductive age who do not agree to use acceptable methods of contraception (oral contraceptives, injectable contraceptive, IUD, hormonal implants, barrier methods, abstinence, hormonal patch and tubal ligation); except surgically sterile (bilateral oophorectomy or hysterectomy);
• Participating in the research that has participated in clinical trial protocols in the last twelve (12) months (CNS Resolution 251 of August 7, 1997, Part III, sub-item J), unless the investigator considers that there may be direct benefit to it;
• Party that has some kinship to the second degree or bond with employees or employees of Sponsor and Research Center;
• Patients with predominant symptoms of reflux or irritable bowel syndrome, warning symptoms, peptic ulcer history or previous surgery in the upper segment of the gastrointestinal tract;
• Patients with prior treatment history of eradication of Helicobacter pylori;
• Patients with kidney, liver or heart failure;
• Patients with past or current history of alcohol abuse;
• Patients with a history of use of antibiotics or bismuth in the 4 weeks prior to study entry, PPIs or H2 blockers, NSAIDs or aspirin in the last two weeks;
• Patients whose endoscopy show changes except hyperemic gastritis, erosive gastritis den considering the maximum of 5 erosions in this location or hiatal hernia;
• Patients whose ultrasonography show hepato-biliopancreatic changes except steatosis.

Related Conditions & MeSH terms

• Helicobacter Pylori Infection

Intervention

Other:
• Food effect

Drug:
• Esomeprazole

• Amoxicillin

• Clarythromycin

Locations

Country	Name	City	State
Brazil	Universidade de São Paulo	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
EMS

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of H pylori eradication		7 days
Secondary	side effects in each of the forms of triple therapy administration and compare them		7 days